Remote monitoring of patients at risk of vision loss from AMD
Notal Vision was founded in order to develop better methods of detecting age-related macular degeneration (AMD) that could allow doctors to treat patients at an earlier stage and possibly prevent any loss of sight. AMD is the leading cause of severe vision loss and blindness in adults over age 55, and destroys sharp, central vision, necessary for common tasks such as facial recognition, driving, reading, and watching television.
There are two types of AMD, dry (non-neovascular) and wet (neovascular). About 90% of significant vision loss and blindness is associated with wet AMD. However, when wet AMD is detected early, the disease progression can often be halted, before irreversible vision loss occurs. Notal Vision's ForeseeHome is the first FDA cleared, teleconnected, home-based system to provide frequent monitoring of AMD patients and enable early detection of visual changes, often before noticeable symptoms.
Using the ForeseeHome, a patient checks his or her vision once-a-day, and in the case of a statistically significant change in test scores, both the patient and doctor are notified immediately to schedule an appointment. Notal Vision's headquarters are located in Tel Aviv, Israel, with a U.S. office and distribution center in St. Louis, MO.